Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1996 3
1997 2
1998 1
1999 1
2000 3
2001 2
2002 1
2003 1
2004 1
2005 3
2006 6
2007 1
2008 5
2009 6
2010 3
2011 3
2012 7
2013 3
2014 3
2015 2
2016 2
2017 4
2018 4
2019 2
2020 5
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Among authors: dulicek p. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: dulicek p. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Lancet Haematol. 2020. PMID: 32014125 Clinical Trial.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: dulicek p. Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634011 Free PMC article. No abstract available.
Treatment of polycythemia vera.
Dulíček P. Dulíček P. Vnitr Lek. 2018 Fall;64(10):955-960. Vnitr Lek. 2018. PMID: 30590943 English.
[Peripartal life-threatening hemorrhage - interdisciplinary consensus opinion].
Kvasnička J, Balík M, Binder T, Blatný J, Bláha J, Cvachovec K, Cerný V, Dulíček P, Feyereisl J, Hájek Z, Janků P, Malý J, Měchurová A, Pařízek A, Penka M, Procházka M, Roztočil A, Reháček V, Seidlová D, Sevčík P, Valenta J, Ventruba P. Kvasnička J, et al. Among authors: dulicek p. Vnitr Lek. 2012 Sep;58(9):661-4. Vnitr Lek. 2012. PMID: 23094811 Czech.
Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.
Reid RL, Westhoff C, Mansour D, de Vries C, Verhaeghe J, Boschitsch E, Gompel A, Birkhäuser M, Krepelka P, Dulicek P, Iversen OE, Khamoshina M, Dezman LV, Fruzzetti F, Szarewski A, Wilken-Jensen C, Seidman D, Kaaja R, Shapiro S. Reid RL, et al. Among authors: dulicek p. J Fam Plann Reprod Health Care. 2010 Jul;36(3):117-22. doi: 10.1783/147118910791749425. J Fam Plann Reprod Health Care. 2010. PMID: 20659363 Free article. No abstract available.
[Thrombophilic states].
Chrobák L, Dulícek P. Chrobák L, et al. Among authors: dulicek p. Vnitr Lek. 1998 Aug;44(8):481-6. Vnitr Lek. 1998. PMID: 10358455 Review. Czech.
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Hasselbalch HC, Kralovics R, Kiladjian JJ. Gisslinger H, et al. Among authors: dulicek p. Hemasphere. 2020 Oct 20;4(6):e485. doi: 10.1097/HS9.0000000000000485. eCollection 2020 Dec. Hemasphere. 2020. PMID: 33134869 Free PMC article. No abstract available.
74 results